<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04400578</url>
  </required_header>
  <id_info>
    <org_study_id>EKS 48/19</org_study_id>
    <nct_id>NCT04400578</nct_id>
  </id_info>
  <brief_title>TRICIN: Prospective Study on the Efficacy of Single Topical Trichloroacetic Acid (TCA) 85% in the Treatment of Cervical Intraepithelial Neoplasia (CIN 1/2)</brief_title>
  <acronym>TRICIN</acronym>
  <official_title>TRICIN: Prospective Study on the Efficacy of Single Topical Trichloroacetic Acid (TCA) 85% in the Treatment of Cervical Intraepithelial Neoplasia (CIN 1/2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Barmherzige Schwestern Linz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Krankenhaus Barmherzige Schwestern Linz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trichloroacetic acid 85% =TCA is an investigational device intended to achieve a complete&#xD;
      histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.&#xD;
      The device system is to be used only in accordance with the approved Investigational Plan on&#xD;
      subjects, who have given written informed consent.&#xD;
&#xD;
      High remission and regression rates are expected after a single topical treatment with 85%&#xD;
      TCA. After a single topical treatment with 85% TCA for CIN 1-2 (Expected 70% or higher; null&#xD;
      hypothesis: not higher than 55%). Regression is defined as improvement from high grade lesion&#xD;
      (CIN 2) at baseline to low grade lesion (CIN 1) after TCA treatment. Regression from CIN 1&#xD;
      normal squamous epithelium after the TCA treatment is equal to remission and will be counted&#xD;
      as a remission in combined analysis. Remission is defined as complete histologic remission of&#xD;
      CIN back to normal squamous epithelium after the TCA treatment, i.e., no cervical dysplasia&#xD;
      is detectable by histology or cytology after the TCA treatment. Type-specific HPV Clearance&#xD;
      is defined as disappearance of the HPV type detected at screening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Visit and assessment Schedule:&#xD;
&#xD;
      Visit1 Screening:&#xD;
&#xD;
        -  Informed Consent,&#xD;
&#xD;
        -  Inclusion/Exclusion Criteria,&#xD;
&#xD;
        -  Medical History,&#xD;
&#xD;
        -  Gynecological Examination&#xD;
&#xD;
        -  Cytology&#xD;
&#xD;
        -  HPV Test&#xD;
&#xD;
        -  Colposcopy&#xD;
&#xD;
        -  Biopsy&#xD;
&#xD;
        -  VAS (Visual analog scale)&#xD;
&#xD;
        -  Pregnancy test&#xD;
&#xD;
      Visit 2 Treatment Day with TCA 85%:&#xD;
&#xD;
        -  Colposcopy&#xD;
&#xD;
        -  TCA Treatment&#xD;
&#xD;
        -  VAS&#xD;
&#xD;
        -  Pregnancy test&#xD;
&#xD;
      Visit 3, Control 1, Week 10-14:&#xD;
&#xD;
        -  Cytology&#xD;
&#xD;
        -  HPV Test&#xD;
&#xD;
        -  Colposcopy&#xD;
&#xD;
        -  Biopsy&#xD;
&#xD;
        -  4-quadrant biopsy&#xD;
&#xD;
        -  ECC&#xD;
&#xD;
        -  Adverse event monitoring If there is no sign of CIN during the colposcopic examination&#xD;
           10-14 weeks a 4-quadrant biopsy and a ECC are performed&#xD;
&#xD;
      Visit 4, Control 2, Week 22-26:&#xD;
&#xD;
        -  Cytology&#xD;
&#xD;
        -  HPV Test&#xD;
&#xD;
        -  Colposcopy&#xD;
&#xD;
        -  Biopsy&#xD;
&#xD;
        -  4-quadrant biopsy&#xD;
&#xD;
        -  ECC&#xD;
&#xD;
        -  Adverse event monitoring&#xD;
&#xD;
        -  Pregnancy test If there is no sign of CIN during the colposcopic examination 22-26 weeks&#xD;
           after the TCA treatment, a 4-quadrant biopsy and a ECC are performed.&#xD;
&#xD;
      Visit 5, EOS , Week 24-30:&#xD;
&#xD;
      - Results Discussion&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CIN remission rate after treatment with TCA 85%</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CIN regression rate after treatment with TCA 85%</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>6 months</time_frame>
    <description>measured by Visual Analogue Scale of a single use of TCA 85% in patients with CIN 1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type specific human papillomavirus clearance rate after treatment with TCA 85%</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">101</enrollment>
  <condition>Cervical Intraepithelial Neoplasia Grade 1</condition>
  <condition>Cervical Intraepithelial Neoplasia Grade 2</condition>
  <arm_group>
    <arm_group_label>TRICIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If a patient is eligible&#xD;
local anesthesia with Xylocain 10% with a pump spray for a period of 10 seconds- one time application&#xD;
Procain 2%: local anesthesia with a swab for a period of 10 seconds- one time application&#xD;
Trichloroacetic acid TCA 85% 1-2 ml with soaked swab for max. 2 minutes -one time application</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trichloroacetic acid 85% (TCA)</intervention_name>
    <description>Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.</description>
    <arm_group_label>TRICIN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven CIN 1/2&#xD;
&#xD;
          -  adequate colposcopy (i.e. fully visible transformation zone and margins of any visible&#xD;
             lesion)&#xD;
&#xD;
          -  positive HPV test&#xD;
&#xD;
          -  conducted negative pregnancy test&#xD;
&#xD;
          -  women aged 18 to 50 years&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria are a cytologically suspected CIN (Pap IIID, IV)&#xD;
&#xD;
          -  inadequate colposcopy&#xD;
&#xD;
          -  negative or missing biopsy&#xD;
&#xD;
          -  cytology results indicating invasive disease (PAP V)&#xD;
&#xD;
          -  if the cervical lesion recedes into the endocervical canal&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  any medical circumstance considered relevant for proper performance of the study, or&#xD;
             risks to the patient, at the discretion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukas Hefler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Barmherzige Schwestern Linz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laudia Hadjari</last_name>
    <phone>+43 732 7677 0</phone>
    <phone_ext>4681</phone_ext>
    <email>laudia.hadjari@ordensklinikum.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of gynaecology, Ordensklinikum Linz Ges.m.b.H, Barmherzige Schwestern</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukas Hefler, MD</last_name>
      <phone>+43 732 7677 0</phone>
      <phone_ext>7160</phone_ext>
      <email>lukas.hefler@ordensklinikum.at</email>
    </contact>
    <contact_backup>
      <last_name>Laudia Hadjari</last_name>
      <phone>+43 732 7677 0</phone>
      <phone_ext>4681</phone_ext>
      <email>laudia.hadjari@ordensklinikum.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

